CYRX Stock Analysis: Cryoport | NASDAQ
Integrated Freight & Logistics | NASDAQ, USA | Market Cap: 781m USD | 12M Return: 115.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.1M
Qual. Beats: 0
Rev. Trend: -86.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cryoport, Inc. (NASDAQ: CYRX), founded in 1999 and headquartered in Brentwood, Tennessee, provides temperature-controlled supply chain solutions across biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company operates through two segments: Life Sciences Services, which offers logistics, biostorage, bioservices, and cryopreservation, and Life Sciences Products, which manufactures and sells cryogenic freezers, dewars, and related accessories.
Its product portfolio includes the Cryoport Express Shippers, Cryoport Elite, the HV3 cryogenic shipping system, and the Smartpak Condition Monitoring System and Tec4Med IoT-based monitoring solutions. The company also offers IntegriCell services covering apheresis collection and cryopreservation, along with bioservices such as controlled temperature storage, kitting, labelling, fulfillment, sample management, and Qualified Person drug product release.
Cryoport operates within the cold chain logistics subsector of healthcare, a niche industry that is increasingly important due to the growth of cell and gene therapies, regenerative medicines, and advanced biologics, all of which require ultra-low temperature preservation (typically at or below -150°C using liquid nitrogen vapor) to maintain product viability throughout transportation and storage.
- Cell and gene therapy approvals accelerate biopharma logistics shipment volume
- Bioservices margin expansion from Cryogene and CLG acquisition integrations
- Competition from specialty pharma couriers pressures pricing on enterprise contracts
| Net Income: 77.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 1.72 > 1.0 |
| NWC/Revenue: 134.3% < 20% (prev 171.2%; Δ -36.95% < -1%) |
| CFO/TA -0.00 > 3% & CFO -503k > Net Income 77.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.9m) vs 12m ago -0.10% < -2% |
| Gross Margin: 47.19% > 18% (prev 45.17%; Δ 2.01% > 0.5%) |
| Asset Turnover: 25.00% > 50% (prev 28.14%; Δ -3.14% > 0%) |
| Interest Coverage Ratio: -14.83 > 6 (EBIT TTM -32.8m / Interest Expense TTM 2.21m) |
| A: 0.32 (Total Current Assets 470.5m - Total Current Liabilities 224.9m) / Total Assets 763.6m |
| B: -0.92 (Retained Earnings -699.4m / Total Assets 763.6m) |
| C: -0.04 (EBIT TTM -32.8m / Avg Total Assets 731.7m) |
| D: 1.84 (Book Value of Equity 495.0m / Total Liabilities 268.6m) |
| Altman-Z'' = 0.76 = B |
| DSRI: 1.48 (Receivables 39.0m/28.4m, Revenue 182.9m/196.9m) |
| GMI: 0.96 (GM 45.17% / 47.19%) |
| AQI: 0.89 (AQ_t 0.21 / AQ_t-1 0.24) |
| SGI: 0.93 (Revenue 182.9m / 196.9m) |
| TATA: 0.10 (NI 77.2m - CFO -503k) / TA 763.6m) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of July 13, 2026, the stock is trading at USD 16.17 with a total of 533,912 shares traded. Over the past week, the price has changed by +4.39%, over one month by +10.60%, over three months by +67.74% and over the past year by +115.60%.
Current recommended Stop Loss: 15.30 (which is 5.4% or 1.3 ATR below the current price).
Cryoport has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CYRX.
- StrongBuy: 4
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.6 | -3.5% |
P/E Forward = 90.9091
P/S = 4.2678
P/B = 1.7333
P/EG = 62.1277
Revenue TTM = 182.9m USD
EBIT TTM = -32.8m USD
EBITDA TTM = -6.31m USD
Long Term Debt = 1.03m USD (from longTermDebt, last quarter)
Short Term Debt = 189.6m USD (from shortTermDebt, last quarter)
Debt = 274.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 43.9m
Net Debt = -129.2m USD (calculated: Debt 274.4m - CCE 403.6m)
Enterprise Value = 651.5m USD (780.7m + Debt 274.4m - CCE 403.6m)
Interest Coverage Ratio = -14.83 (Ebit TTM -32.8m / Interest Expense TTM 2.21m)
EV/FCF = -26.74x (Enterprise Value 651.5m / FCF TTM -24.4m)
FCF Yield = -3.74% (FCF TTM -24.4m / Enterprise Value 651.5m)
FCF Margin = -13.32% (FCF TTM -24.4m / Revenue TTM 182.9m)
Net Margin = 42.18% (Net Income TTM 77.2m / Revenue TTM 182.9m)
Gross Margin = 47.19% ((Revenue TTM 182.9m - Cost of Revenue TTM 96.6m) / Revenue TTM)
Gross Margin QoQ = 45.85% (prev 47.77%)
Tobins Q-Ratio = 0.85 (Enterprise Value 651.5m / Total Assets 763.6m)
Interest Expense / Debt = 0.81% (Interest Expense 2.21m / Debt 274.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -25.9m (EBIT -32.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.09 (Total Current Assets 470.5m / Total Current Liabilities 224.9m)
Debt / Equity = 0.55 (Debt 274.4m / totalStockholderEquity, last quarter 495.0m)
Debt / EBITDA = 20.47 (negative EBITDA) (Net Debt -129.2m / EBITDA -6.31m)
Debt / FCF = 5.30 (negative FCF - burning cash) (Net Debt -129.2m / FCF TTM -24.4m)
Total Stockholder Equity = 477.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.55% (Net Income 77.2m / Total Assets 763.6m)
RoE = 16.16% (Net Income TTM 77.2m / Total Stockholder Equity 477.4m)
RoCE = -6.85% (EBIT -32.8m / Capital Employed (Equity 477.4m + L.T.Debt 1.03m))
RoIC = -3.60% (negative operating profit) (NOPAT -25.9m / Invested Capital 719.2m)
WACC = 9.17% (E(780.7m)/V(1.06b) * Re(12.17%) + D(274.4m)/V(1.06b) * Rd(0.81%) * (1-Tc(0.21)))
Discount Rate = 12.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.89 | Cagr: 0.84%
[DCF] Fair Price = unknown (Cash Flow -24.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -86.32 | Revenue CAGR: -9.45% | SUE: 0.28 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.18 | Chg30d=-7.82% | Revisions=+25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.16 | Chg30d=-8.87% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.73 | Chg30d=-12.82% | Revisions=-17% | GrowthEPS=-8.1% | GrowthRev=+10.3%
EPS next Year (2027-12-31): EPS=-0.62 | Chg30d=-8.77% | Revisions=+40% | GrowthEPS=+15.4% | GrowthRev=+9.6%
[Analyst] Revisions Ratio: +30% (up=5, down=2)